Netscientific Share Discussion Threads

[loafofbread] 07/12/2022 16:56

Proaxis tweeting about the launch of 'K-Postn' which is the product deal they did with Uni of Geneva.

Assume one of the 7 products they now have for sale from the recent interview.

Very good news, if a bit delayed!

ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
FEBRUARY 21, 2021-POSTED BY DAVID RIBEIRO
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of Geneva and the University Hospital of Geneva, today announce that they have reached agreement on a global licensing agreement. Researchers at the University have developed a highly novel assay for a Cathepsin K-dependent periostin cleavage product, as a biomarker of bone fragility related to disorders such as osteoporosis. The technology is currently the subject of patent applications in Europe and the US. As a result of this agreement, ProAxsis will complete the technical validation of the assay, and seek to commercialise the assay in key territories before the end of 2021.

Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:

“We believe this assay will allow the rapid non‐invasive identification of subjects at high risk of osteoporotic fractures and potentially other metabolic bone diseases. This is an incredibly exciting addition to our product portfolio and fits with our business growth plans; including identifying and in-licensing diagnostic tools which fulfil a high unmet need.”

Professor Serge Ferrari, Head of Bone Diseases at the University of Geneva and one of the inventors of the assay technology, said:

“Fragility fractures are a major clinical and public health issue, yet identification of subjects at high risk of fracture remains challenging. The high specificity of the Cathepsin K digested periostin fragment for bone thus presents itself as an ideal candidate to improve prediction of bone fragility.”

Dr Jennifer Cadby, Licensing Officer at the University of Geneva, added:

“We’re delighted to have signed this agreement with ProAxsis and are excited to combine the expertise of the groups in Geneva and Belfast.”

Any enquiries concerning ProAxsis’ product portfolio can be directed to [e-mail]. For further information on the University of Geneva, please visit www.unige.ch

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

[kingston78] 06/12/2022 13:45

It would appear to me that market makers mark down the price on low selling volume whereas they don't mark up the price by as much on low buying volume.

[blakieboy7] 06/12/2022 11:23

This share never fails to disappoint

[blakieboy7] 02/12/2022 20:34

PDSB pushing hard for a strong finish - 9.9USD

[blakieboy7] 02/12/2022 10:19

Share price seems stuck around the placing price

[senttothegallows] 02/12/2022 10:10

No Loaf

So many don't do research and just trade the breeze. It is fairly simple keep adding value will correct at some point. This should be more than double. Pdsb will be bought out at some point capital distribution of more than current share price at that point IMHO

[loafofbread] 02/12/2022 09:48

I wonder if anyone will notice when the value of our PDSB stake is worth more than our entire MCap?

[blakieboy7] 02/12/2022 08:18

70p mid, getting there

[blakieboy7] 02/12/2022 08:05

Nice start. Would be good to crack 70p

[blakieboy7] 01/12/2022 18:34

PDSB breached 10 USD

[blakieboy7] 01/12/2022 18:17

PDSB @ 9.9 USD

[senttothegallows] 01/12/2022 16:55

This puts PDSB in perspective from March

including a $6.1mn (£5mn) stake in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB: US$4.56) Netscientific at the time was 80p.

Your kidding me if 67p is the right price

IMHO

[kingston78] 01/12/2022 16:37

PDSB is currently up by another 7% to US$ 9.67. It is definitely a breakout. I would not be surprised that a pharma major will bid for it.

[blakieboy7] 01/12/2022 16:27

PDB 9.61 breaking out

[kingston78] 01/12/2022 16:11

If you look at the share chart the price spiked from 50 p to over 200 p on an intraday basis in June 2021. History repeats itself, and I believe that similar event will happen, for example, flotation of an existing portfolio company, joint venture, private trade sale, MBO etc each one will realise millions of pounds for NCSI.

[blakieboy7] 01/12/2022 16:10

PDSB 9.54 USD

[senttothegallows] 01/12/2022 15:39

NSCI underlying NAV will currently be circa £2 not sure how many breakthrough's they need should be over £1.30 now. Market and investors are dopey and asleep IMHO

[blakieboy7] 01/12/2022 12:50

Several brokers have increased their pdsb target price to 19USD

[kingston78] 01/12/2022 12:00

A few months ago, the share price of PDSB dropped to a price level of US$ 3.50 or thereabout. Yesterday it went up to US$ 9.03 with a consensus one year target of US$ 16. It is surprising that investors have not caught on this fact, and allow NSCI to languish at the current level, which is below the last placing price.

I am confident that there will be a breakthrough news announcement by any one of its portfolio companies to propel NSCI to at least 130 p within the next six months.

[blakieboy7] 30/11/2022 20:55

PDSB finishing strongly again - back over 9USD

[investordave] 29/11/2022 08:24

It looks like it.

[loafofbread] 29/11/2022 07:55

Positive update from Sofant and a good finish from PDSB.

No doubt both will be ignored!

[loafofbread] 28/11/2022 08:03

Should help QBOT.

An extra £1bn will be spent to insulate the UK's least energy efficient homes, the business secretary has said.
Grant Shapps said the new funding was part of a strategy of working towards "an energy independent future" for the UK and would save those who benefitted around £310 a year.
The ECO+ scheme will target homes that have a low energy efficiency rating and are in the lower council tax bands.
A portion of the funds will be spent on the most vulnerable households.
The Department for Business, Energy, Industry and Skills (Beis) said households who currently did not benefit from any other government support would be able to upgrade their homes under the expansion of the scheme.
A new £18m public information campaign will also offer advice on how to reduce energy use in the home, "without sacrificing comfort", Beis said. The advice will include turning down boiler temperatures and radiators to save energy.
Mr Shapps said the ECO+ scheme would "enable thousands more to insulate their homes, protecting the pounds in their pockets and creating jobs across the country".
The scheme will run from spring 2023 for up to three years, and will focus on low-cost measures such as loft and cavity wall insulation and upgrades to heating. The average cost per home is expected to be £1,500.
An already existing ECO scheme is targeted at people in social housing, on low incomes or who are fuel poor.
However, under the expanded scheme, people whose homes have an energy efficiency rating of D or below can get help, whether they are in private, rented or social housing. If you are eligible, your energy firm will do a survey and pay for the improvements.
Poorer homes to get £1.5bn energy efficiency help
How can better insulation cut energy bills?
Sunak to expand energy-saving tips campaign
The announcement has been welcomed by fuel poverty campaigners but they also say more needs to be done to help those most in need.
Adam Scorer, chief executive of National Energy Action, said the "scheme is not designed to reach the most vulnerable, it's designed to reach people who haven't been able to benefit from previous schemes.
"We believe government focus should be on the worst first, helping people in the greatest risk, the greatest jeopardy, more of this money should be going to help them."